» Articles » PMID: 38464530

Protective Role of Complement Factor H Against the Development of Preeclampsia

Abstract

Pregnancy is an immunologically regulated, complex process. A tightly controlled complement system plays a crucial role in the successful establishment of pregnancy and parturition. Complement inhibitors at the feto-maternal interface are likely to prevent inappropriate complement activation to protect the fetus. In the present study, we aimed to understand the role of Factor H (FH), a negative regulator of complement activation, in normal pregnancy and in a model of pathological pregnancy, preeclampsia (PE). The distribution and expression of FH was investigated in placental tissues, various placental cells, and in the sera of healthy (CTRL) or PE pregnant women immunohistochemistry, RT-qPCR, ELISA, and Western blot. Our results showed a differential expression of FH among the placental cell types, decidual stromal cells (DSCs), decidual endothelial cells (DECs), and extravillous trophoblasts (EVTs). Interestingly, FH was found to be considerably less expressed in the placental tissues of PE patients compared to normal placental tissue both at mRNA and protein levels. Similar results were obtained by measuring circulating FH levels in the sera of third trimester CTRL and PE mothers. Syncytiotrophoblast microvesicles, isolated from the placental tissues of PE and CTRL women, downregulated FH expression by DECs. The present study appears to suggest that FH is ubiquitously present in the normal placenta and plays a homeostatic role during pregnancy.

Citing Articles

Low Levels of Complement Factor H in the First Trimester of Pregnancy Are Associated with Spontaneous Preterm Birth.

Becerra-Mojica C, Mora-Guevara E, Parra-Saavedra M, Martinez-Vega R, Diaz-Martinez L, Rincon-Orozco B Int J Mol Sci. 2024; 25(19).

PMID: 39408876 PMC: 11476428. DOI: 10.3390/ijms251910549.


Systematic review of the complement components as potential biomarkers of pre-eclampsia: pitfalls and opportunities.

Balduit A, Agostinis C, Mangogna A, Zito G, Stampalija T, Ricci G Front Immunol. 2024; 15:1419540.

PMID: 38983853 PMC: 11232388. DOI: 10.3389/fimmu.2024.1419540.

References
1.
Valenzuela F, Perez-Sepulveda A, Torres M, Correa P, Repetto G, Illanes S . Pathogenesis of preeclampsia: the genetic component. J Pregnancy. 2011; 2012:632732. PMC: 3235819. DOI: 10.1155/2012/632732. View

2.
Baig S, Kothandaraman N, Manikandan J, Rong L, Ee K, Hill J . Proteomic analysis of human placental syncytiotrophoblast microvesicles in preeclampsia. Clin Proteomics. 2014; 11(1):40. PMC: 4247627. DOI: 10.1186/1559-0275-11-40. View

3.
Laresgoiti-Servitje E . A leading role for the immune system in the pathophysiology of preeclampsia. J Leukoc Biol. 2013; 94(2):247-57. DOI: 10.1189/jlb.1112603. View

4.
Rodriguez de Cordoba S, Rubinstein P . Quantitative variations of the C3b/C4b receptor (CR1) in human erythrocytes are controlled by genes within the regulator of complement activation (RCA) gene cluster. J Exp Med. 1986; 164(4):1274-83. PMC: 2188423. DOI: 10.1084/jem.164.4.1274. View

5.
Redman C, Sargent I . Immunology of pre-eclampsia. Am J Reprod Immunol. 2010; 63(6):534-43. DOI: 10.1111/j.1600-0897.2010.00831.x. View